Treatment of polymyalgia rheumatica.
Identifieur interne : 000681 ( Main/Exploration ); précédent : 000680; suivant : 000682Treatment of polymyalgia rheumatica.
Auteurs : Santos Casta Eda [Espagne] ; Noelia García-Casta Eda [Espagne] ; Diana Prieto-Pe A [Espagne] ; Dolores Martínez-Quintanilla [Espagne] ; Esther F. Vicente [Espagne] ; Ricardo Blanco [Espagne] ; Miguel A. González-Gay [Afrique du Sud]Source :
- Biochemical pharmacology [ 1873-2968 ] ; 2019.
Descripteurs français
- KwdFr :
- Glucocorticoïdes (usage thérapeutique), Humains, Janus kinases (antagonistes et inhibiteurs), Méthotrexate (usage thérapeutique), Rhumatisme inflammatoire des ceintures (), Rhumatisme inflammatoire des ceintures (diagnostic), Rhumatisme inflammatoire des ceintures (traitement médicamenteux), Rhumatisme inflammatoire des ceintures (étiologie), Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs).
- MESH :
- antagonistes et inhibiteurs : Janus kinases, Récepteurs à l'interleukine-6.
- diagnostic : Rhumatisme inflammatoire des ceintures.
- traitement médicamenteux : Rhumatisme inflammatoire des ceintures.
- usage thérapeutique : Glucocorticoïdes, Méthotrexate.
- étiologie : Rhumatisme inflammatoire des ceintures.
- Humains, Rhumatisme inflammatoire des ceintures.
English descriptors
- KwdEn :
- Glucocorticoids (therapeutic use), Humans, Janus Kinases (antagonists & inhibitors), Methotrexate (therapeutic use), Polymyalgia Rheumatica (complications), Polymyalgia Rheumatica (diagnosis), Polymyalgia Rheumatica (drug therapy), Polymyalgia Rheumatica (etiology), Receptors, Interleukin-6 (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Janus Kinases, Receptors, Interleukin-6.
- chemical , therapeutic use : Glucocorticoids, Methotrexate.
- complications : Polymyalgia Rheumatica.
- diagnosis : Polymyalgia Rheumatica.
- drug therapy : Polymyalgia Rheumatica.
- etiology : Polymyalgia Rheumatica.
- Humans.
Abstract
Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral pain involving predominantly the shoulders and proximal aspects of the arms and less commonly the neck and the pelvic girdle. This review discusses briefly the main epidemiological data and clinical features of this condition. Especial attention is paid in the management of the disease. For this reason, both the classic management and the impact of new therapies are discussed in depth. In general, patients with PMR experience a rapid response to 12.5-25 mg/prednisone/day in less than a week. Patients with poor response to glucocorticoids or with relapsing disease require other therapies aimed mainly to spare glucocorticoids. Among them, methotrexate is the most commonly used. Nevertheless, different studies indicate that this agent yields only a modest effect. Biologic therapies against the main cytokines involved in the pathogenesis of the disease have been used in refractory patients. However, randomized controlled trials do not support the use of anti-tumor necrosis factor agents in PMR. In contrast, several case series and retrospective studies highlight the efficacy of the anti-interleukin-6 receptor tocilizumab in PMR. Nonetheless, controlled trials are needed to fully establish the beneficial effect of this agent. The potential favorable effect of the Janus-kinase inhibitors and new anti-interleukin-6 antagonists remains to be determined.
DOI: 10.1016/j.bcp.2019.03.027
PubMed: 30904473
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000442
- to stream PubMed, to step Curation: 000442
- to stream PubMed, to step Checkpoint: 000263
- to stream Ncbi, to step Merge: 001E70
- to stream Ncbi, to step Curation: 001E70
- to stream Ncbi, to step Checkpoint: 001E70
- to stream Main, to step Merge: 000681
- to stream Main, to step Curation: 000681
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of polymyalgia rheumatica.</title><author><name sortKey="Casta Eda, Santos" sort="Casta Eda, Santos" uniqKey="Casta Eda S" first="Santos" last="Casta Eda">Santos Casta Eda</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: scastas@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Garcia Casta Eda, Noelia" sort="Garcia Casta Eda, Noelia" uniqKey="Garcia Casta Eda N" first="Noelia" last="García-Casta Eda">Noelia García-Casta Eda</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: ngcastaneda@salud.madrid.org.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Prieto Pe A, Diana" sort="Prieto Pe A, Diana" uniqKey="Prieto Pe A D" first="Diana" last="Prieto-Pe A">Diana Prieto-Pe A</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Electronic address: diana.prieto@scsalud.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Quintanilla, Dolores" sort="Martinez Quintanilla, Dolores" uniqKey="Martinez Quintanilla D" first="Dolores" last="Martínez-Quintanilla">Dolores Martínez-Quintanilla</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: lolamqj@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Vicente, Esther F" sort="Vicente, Esther F" uniqKey="Vicente E" first="Esther F" last="Vicente">Esther F. Vicente</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: efvicenter@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Electronic address: rblanco@humv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez Gay, Miguel A" sort="Gonzalez Gay, Miguel A" uniqKey="Gonzalez Gay M" first="Miguel A" last="González-Gay">Miguel A. González-Gay</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: miguelaggay@hotmail.com.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30904473</idno><idno type="pmid">30904473</idno><idno type="doi">10.1016/j.bcp.2019.03.027</idno><idno type="wicri:Area/PubMed/Corpus">000442</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000442</idno><idno type="wicri:Area/PubMed/Curation">000442</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000442</idno><idno type="wicri:Area/PubMed/Checkpoint">000263</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000263</idno><idno type="wicri:Area/Ncbi/Merge">001E70</idno><idno type="wicri:Area/Ncbi/Curation">001E70</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E70</idno><idno type="wicri:Area/Main/Merge">000681</idno><idno type="wicri:Area/Main/Curation">000681</idno><idno type="wicri:Area/Main/Exploration">000681</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of polymyalgia rheumatica.</title><author><name sortKey="Casta Eda, Santos" sort="Casta Eda, Santos" uniqKey="Casta Eda S" first="Santos" last="Casta Eda">Santos Casta Eda</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: scastas@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Garcia Casta Eda, Noelia" sort="Garcia Casta Eda, Noelia" uniqKey="Garcia Casta Eda N" first="Noelia" last="García-Casta Eda">Noelia García-Casta Eda</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: ngcastaneda@salud.madrid.org.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Prieto Pe A, Diana" sort="Prieto Pe A, Diana" uniqKey="Prieto Pe A D" first="Diana" last="Prieto-Pe A">Diana Prieto-Pe A</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Electronic address: diana.prieto@scsalud.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Quintanilla, Dolores" sort="Martinez Quintanilla, Dolores" uniqKey="Martinez Quintanilla D" first="Dolores" last="Martínez-Quintanilla">Dolores Martínez-Quintanilla</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: lolamqj@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Vicente, Esther F" sort="Vicente, Esther F" uniqKey="Vicente E" first="Esther F" last="Vicente">Esther F. Vicente</name><affiliation wicri:level="4"><nlm:affiliation>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Electronic address: efvicenter@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra Roche-UAM, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Electronic address: rblanco@humv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez Gay, Miguel A" sort="Gonzalez Gay, Miguel A" uniqKey="Gonzalez Gay M" first="Miguel A" last="González-Gay">Miguel A. González-Gay</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: miguelaggay@hotmail.com.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author></analytic><series><title level="j">Biochemical pharmacology</title><idno type="eISSN">1873-2968</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Janus Kinases (antagonists & inhibitors)</term><term>Methotrexate (therapeutic use)</term><term>Polymyalgia Rheumatica (complications)</term><term>Polymyalgia Rheumatica (diagnosis)</term><term>Polymyalgia Rheumatica (drug therapy)</term><term>Polymyalgia Rheumatica (etiology)</term><term>Receptors, Interleukin-6 (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Janus kinases (antagonistes et inhibiteurs)</term><term>Méthotrexate (usage thérapeutique)</term><term>Rhumatisme inflammatoire des ceintures ()</term><term>Rhumatisme inflammatoire des ceintures (diagnostic)</term><term>Rhumatisme inflammatoire des ceintures (traitement médicamenteux)</term><term>Rhumatisme inflammatoire des ceintures (étiologie)</term><term>Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Janus Kinases</term><term>Receptors, Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glucocorticoids</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Janus kinases</term><term>Récepteurs à l'interleukine-6</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Polymyalgia Rheumatica</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Polymyalgia Rheumatica</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Rhumatisme inflammatoire des ceintures</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Polymyalgia Rheumatica</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Polymyalgia Rheumatica</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Rhumatisme inflammatoire des ceintures</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Glucocorticoïdes</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Rhumatisme inflammatoire des ceintures</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Rhumatisme inflammatoire des ceintures</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral pain involving predominantly the shoulders and proximal aspects of the arms and less commonly the neck and the pelvic girdle. This review discusses briefly the main epidemiological data and clinical features of this condition. Especial attention is paid in the management of the disease. For this reason, both the classic management and the impact of new therapies are discussed in depth. In general, patients with PMR experience a rapid response to 12.5-25 mg/prednisone/day in less than a week. Patients with poor response to glucocorticoids or with relapsing disease require other therapies aimed mainly to spare glucocorticoids. Among them, methotrexate is the most commonly used. Nevertheless, different studies indicate that this agent yields only a modest effect. Biologic therapies against the main cytokines involved in the pathogenesis of the disease have been used in refractory patients. However, randomized controlled trials do not support the use of anti-tumor necrosis factor agents in PMR. In contrast, several case series and retrospective studies highlight the efficacy of the anti-interleukin-6 receptor tocilizumab in PMR. Nonetheless, controlled trials are needed to fully establish the beneficial effect of this agent. The potential favorable effect of the Janus-kinase inhibitors and new anti-interleukin-6 antagonists remains to be determined.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Espagne</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement><orgName><li>Université autonome de Madrid</li></orgName></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Casta Eda, Santos" sort="Casta Eda, Santos" uniqKey="Casta Eda S" first="Santos" last="Casta Eda">Santos Casta Eda</name></region><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name><name sortKey="Garcia Casta Eda, Noelia" sort="Garcia Casta Eda, Noelia" uniqKey="Garcia Casta Eda N" first="Noelia" last="García-Casta Eda">Noelia García-Casta Eda</name><name sortKey="Martinez Quintanilla, Dolores" sort="Martinez Quintanilla, Dolores" uniqKey="Martinez Quintanilla D" first="Dolores" last="Martínez-Quintanilla">Dolores Martínez-Quintanilla</name><name sortKey="Prieto Pe A, Diana" sort="Prieto Pe A, Diana" uniqKey="Prieto Pe A D" first="Diana" last="Prieto-Pe A">Diana Prieto-Pe A</name><name sortKey="Vicente, Esther F" sort="Vicente, Esther F" uniqKey="Vicente E" first="Esther F" last="Vicente">Esther F. Vicente</name></country><country name="Afrique du Sud"><noRegion><name sortKey="Gonzalez Gay, Miguel A" sort="Gonzalez Gay, Miguel A" uniqKey="Gonzalez Gay M" first="Miguel A" last="González-Gay">Miguel A. González-Gay</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30904473
|texte= Treatment of polymyalgia rheumatica.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30904473" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |